Clinical Trial

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor Receptor) mutation-harboring patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06926413
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Non Small Cell Lung Cancer
Enrollment 20 participants
Start Date 2025-02-20
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-13